Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
December 17, 2024 08:05 ET
|
Scienture Holdings, Inc.
TAMPA, FL, Dec. 17, 2024 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (the “Company”) (NASDAQ: SCNX), a specialty pharma company with a novel pipeline of brand products, is pleased to announce its...
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
December 10, 2024 08:05 ET
|
Scienture Holdings, Inc.
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and...
Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement
November 26, 2024 16:05 ET
|
Scienture Holdings, Inc.
Scienture Holdings to Receive Funding of Up to $12 Million From Private Placement of 10% Secured Convertible Debentures and Up to $50 Million from Equity Line of Credit Tampa, FL, Nov. 26, 2024 ...
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
September 24, 2024 08:01 ET
|
Scienture Holdings, Inc.
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed company. ...
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
September 20, 2024 11:59 ET
|
Trxade Health, Inc.
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced...
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC’s Executive Leadership Team
August 05, 2024 08:01 ET
|
Trxade Health, Inc.
TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced the...
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
July 26, 2024 08:01 ET
|
Trxade Health, Inc.
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and...
TRxADE Health, Inc. Announces Special Cash Dividend
July 09, 2024 08:05 ET
|
Trxade Health, Inc.
TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (Nasdaq: MEDS) (the “Company”), announced that the Company’s board of directors has declared a special cash dividend of $1.50 per...
TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale
June 27, 2024 08:00 ET
|
Trxade Health, Inc.
TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced today that with the filing of its Quarterly Report on Form 10-Q for the period ended March...
TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
May 29, 2024 16:05 ET
|
Trxade Health, Inc.
TAMPA, FL, May 29, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (Nasdaq: MEDS) (the “Company”), announced that, on May 23, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing...